ASH News Daily 2017 - Issue 1 - B-20
ASH NewS DAily
Page B-20
®
NOW ENROLLING
MiNoRity RecRuitMeNt iNitiAtive
A Phase 3 Randomized, Controlled, Open-label
Study of Selinexor, Bortezomib, and
Dexamethasone (SVd) versus Bortezomib and
Dexamethasone (Vd) in Patients with
Relapsed or Refractory Multiple Myeloma
SVd
1:1
Randomization
selinexor, bortezomib
& dexamethasone
Progression
Free
Survival
Vd
PROGRESSIVE
bortezomib &
dexamethasone
DISEASE
SVd
& Safety
selinexor, bortezomib
& dexamethasone
Crossover for patients progressing on Vd
Phase III Study
with Crossover Design
This open-label study will compare the efficacy
and assess the safety of oral selinexor
plus bortezomib (Velcade® once weekly) plus
low-dose dexamethasone (SVd) versus
bortezomib (twice weekly) plus low-dose
dexamethasone (Vd) in patients with Relapsed
or Refractory Multiple Myeloma
* Global trial enrolling ~360 patients with
1-3 prior lines of anti-myeloma therapy
* Both bortezomib-exposed and
bortezomib-naïve patients allowed
* SVd Arm: once weekly injection of
bortezomib for 4 out of 5 weeks
* Vd Arm: twice weekly bortezomib injection
2 out of 3 weeks x 8 cycles, then once
weekly 4 out of 5 weeks
* For Vd arm, crossover to SVd permitted
once progression is confirmed
ASH Announces 2017
Minority Graduate Student
Abstract Achievement Awards
T
he Minority Graduate Student Abstract Achievement
Award is part of the ASH
Abstract Achievement Award
program. This award program is
meant to encourage minority graduate students in the field of hematology and is part of the broader
Minority Recruitment Initiative
at ASH, which also includes the
Minority Medical Student Award
Program (MMSAP), the Minority Resident Hematology Award
Program, and the ASH-Harold
Amos Medical Faculty Development Program (ASH-AMFDP) in
partnership with the Robert Wood
Johnson Foundation. The goal of
the Minority Graduate Student
Abstract Achievement Award is
to attract and retain minority PhD
students to the field of hematology
through the ASH annual meeting.
At this meeting, students will have
the opportunity to hear the latest
advances in hematology-related
research and interact with ASH
leadership, senior researchers, and
minority physicians, scientists, and
students. These awards go to select
graduate students to acknowledge
their accomplishments in the field
of hematology.
sion in Hematologic Malignancy,
including Disordered Epigenetic
Regulation: Poster III
Monday, December 11, 2017, 6:00
p.m.-8:00 p.m., Hall A2 (Georgia
World Congress Center)
Sierrah Grigsby
University of Michigan
Abstract 3785
Title: The AF9-Binding Domain
of DOT1L Is Critical for Its Recruitment By MLL Fusion Proteins in
Leukemia and Contributes to Its
Functions in Normal Hematopoiesis
602. Disordered Gene Expres-
Ian Johnston
Perelman School of Medicine
Abstract 2310
Title: Platelet Factor 4 Binds to
Released Von Willebrand Factor
Strands from Injured Endothelium
and Forms a Prothrombotic HIT
VELCADE is a registered trademark of Millennium Pharmaceuticals, Inc.
To learn more visit www.clinicaltrials.gov
Mojibade Hassan
Emory University
Abstract 4431
Title: Reduced GvHD in Recipients of BM Derived Versus G-CSF
Mobilized Plasmacytoid Dendritic
Cells: Role of Inducible IL-12
701. Experimental Transplantation: Basic Biology, Pre-Clinical
Models: Poster III
Monday, December 11, 2017, 6:00
p.m.-8:00 p.m., Hall A2 (Georgia
World Congress Center)
»» MGSAAA Page B-48
Abstracts
Saturday, December 9, 4:00
p.m.-5:30 p.m., B213-B214 (Georgia World Congress Center)
ASH-SIE Abstract
Achievement Award
Antonella Nai, PhD
IRCCS San Raffaele Scientific
Institute
Abstract #224
Title: The Macrophage Nuclear
Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia
102. Regulation of Iron Metabolism: Iron Homeostasis and
Related Pathophysiology
Giorgia Federico, PhD
University of Naples Federico II
Abstract #223
Title: NCOA4 Links Iron Bioavailability to DNA Metabolism
102. Regulation of Iron Metabolism: Iron homeostasis and
related pathophysiology
Saturday, December 9, 4:00
p.m.-5:30 p.m., B213-B214 (Georgia World Congress Center)
«« From Page B-4
Selinexor is an investigational agent, and safety and
efficacy have not been established by any agency
Lucas Gutierrez
University of Southern California
Abstract 2621
Title: Midostaurin Reduces Regulatory T Cell Population in Healthy
and Acute Myeloid Leukemia Cells
616. Acute Myeloid Leukemia:
Novel Therapy, excluding Transplantation: Poster II
Sunday, December 10, 2017, 6:00
p.m.-8:00 p.m., Hall A2 (Georgia
World Congress Center)
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 1
ASH News Daily 2017 - Issue 1 - A-1
ASH News Daily 2017 - Issue 1 - A-2
ASH News Daily 2017 - Issue 1 - A-3
ASH News Daily 2017 - Issue 1 - A-4
ASH News Daily 2017 - Issue 1 - A-5
ASH News Daily 2017 - Issue 1 - A-6
ASH News Daily 2017 - Issue 1 - A-7
ASH News Daily 2017 - Issue 1 - A-8
ASH News Daily 2017 - Issue 1 - A-9
ASH News Daily 2017 - Issue 1 - A-10
ASH News Daily 2017 - Issue 1 - A-11
ASH News Daily 2017 - Issue 1 - A-12
ASH News Daily 2017 - Issue 1 - A-13
ASH News Daily 2017 - Issue 1 - A-14
ASH News Daily 2017 - Issue 1 - A-15
ASH News Daily 2017 - Issue 1 - A-16
ASH News Daily 2017 - Issue 1 - A-17
ASH News Daily 2017 - Issue 1 - A-18
ASH News Daily 2017 - Issue 1 - A-19
ASH News Daily 2017 - Issue 1 - A-20
ASH News Daily 2017 - Issue 1 - A-21
ASH News Daily 2017 - Issue 1 - A-22
ASH News Daily 2017 - Issue 1 - A-23
ASH News Daily 2017 - Issue 1 - A-24
ASH News Daily 2017 - Issue 1 - A-25
ASH News Daily 2017 - Issue 1 - A-26
ASH News Daily 2017 - Issue 1 - A-27
ASH News Daily 2017 - Issue 1 - A-28
ASH News Daily 2017 - Issue 1 - B-1
ASH News Daily 2017 - Issue 1 - B-2
ASH News Daily 2017 - Issue 1 - B-3
ASH News Daily 2017 - Issue 1 - B-4
ASH News Daily 2017 - Issue 1 - B-5
ASH News Daily 2017 - Issue 1 - B-6
ASH News Daily 2017 - Issue 1 - B-7
ASH News Daily 2017 - Issue 1 - B-8
ASH News Daily 2017 - Issue 1 - B-9
ASH News Daily 2017 - Issue 1 - B-10
ASH News Daily 2017 - Issue 1 - B-11
ASH News Daily 2017 - Issue 1 - B-12
ASH News Daily 2017 - Issue 1 - B-13
ASH News Daily 2017 - Issue 1 - B-14
ASH News Daily 2017 - Issue 1 - B-15
ASH News Daily 2017 - Issue 1 - B-16
ASH News Daily 2017 - Issue 1 - B-17
ASH News Daily 2017 - Issue 1 - B-18
ASH News Daily 2017 - Issue 1 - B-19
ASH News Daily 2017 - Issue 1 - B-20
ASH News Daily 2017 - Issue 1 - B-21
ASH News Daily 2017 - Issue 1 - B-22
ASH News Daily 2017 - Issue 1 - B-23
ASH News Daily 2017 - Issue 1 - B-24
ASH News Daily 2017 - Issue 1 - B-25
ASH News Daily 2017 - Issue 1 - B-26
ASH News Daily 2017 - Issue 1 - B-27
ASH News Daily 2017 - Issue 1 - B-30
ASH News Daily 2017 - Issue 1 - B-31
ASH News Daily 2017 - Issue 1 - B-32
ASH News Daily 2017 - Issue 1 - B-33
ASH News Daily 2017 - Issue 1 - B-34
ASH News Daily 2017 - Issue 1 - B-35
ASH News Daily 2017 - Issue 1 - B-36
ASH News Daily 2017 - Issue 1 - B-37
ASH News Daily 2017 - Issue 1 - B-38
ASH News Daily 2017 - Issue 1 - B-39
ASH News Daily 2017 - Issue 1 - B-40
ASH News Daily 2017 - Issue 1 - B-41
ASH News Daily 2017 - Issue 1 - B-42
ASH News Daily 2017 - Issue 1 - B-43
ASH News Daily 2017 - Issue 1 - B-44
ASH News Daily 2017 - Issue 1 - B-45
ASH News Daily 2017 - Issue 1 - B-46
ASH News Daily 2017 - Issue 1 - B-47
ASH News Daily 2017 - Issue 1 - B-48
ASH News Daily 2017 - Issue 1 - B-49
ASH News Daily 2017 - Issue 1 - B-50
ASH News Daily 2017 - Issue 1 - B-51
ASH News Daily 2017 - Issue 1 - B-52
ASH News Daily 2017 - Issue 1 - B-53
ASH News Daily 2017 - Issue 1 - B-54
ASH News Daily 2017 - Issue 1 - B-55
ASH News Daily 2017 - Issue 1 - B-56
ASH News Daily 2017 - Issue 1 - C-1
ASH News Daily 2017 - Issue 1 - C-2
ASH News Daily 2017 - Issue 1 - C-3
ASH News Daily 2017 - Issue 1 - C-4
ASH News Daily 2017 - Issue 1 - C-5
ASH News Daily 2017 - Issue 1 - C-6
ASH News Daily 2017 - Issue 1 - C-7
ASH News Daily 2017 - Issue 1 - C-8
ASH News Daily 2017 - Issue 1 - C-9
ASH News Daily 2017 - Issue 1 - C-10
ASH News Daily 2017 - Issue 1 - C-11
ASH News Daily 2017 - Issue 1 - C-12
ASH News Daily 2017 - Issue 1 - C-13
ASH News Daily 2017 - Issue 1 - C-14
ASH News Daily 2017 - Issue 1 - C-15
ASH News Daily 2017 - Issue 1 - C-16
ASH News Daily 2017 - Issue 1 - C-17
ASH News Daily 2017 - Issue 1 - C-18
ASH News Daily 2017 - Issue 1 - C-19
ASH News Daily 2017 - Issue 1 - C-20
ASH News Daily 2017 - Issue 1 - C-21
ASH News Daily 2017 - Issue 1 - C-22
ASH News Daily 2017 - Issue 1 - C-23
ASH News Daily 2017 - Issue 1 - C-24
ASH News Daily 2017 - Issue 1 - C-25
ASH News Daily 2017 - Issue 1 - C-26
ASH News Daily 2017 - Issue 1 - C-27
ASH News Daily 2017 - Issue 1 - C-28
ASH News Daily 2017 - Issue 1 - C-29
ASH News Daily 2017 - Issue 1 - C-30
ASH News Daily 2017 - Issue 1 - C-31
ASH News Daily 2017 - Issue 1 - C-32
https://www.nxtbookmedia.com